An interventional study of perineural injection and Physiotherapy in Adhesive Capsulitis, sponsored by Universiti Teknologi Mara. Recruiting at 1 site in Malaysia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-04.
Sponsored by Universiti Teknologi Mara · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if Perineural Injection Therapy (PIT) works to treat adhesive capsulitis (frozen shoulder) in adults. It will also learn about the safety of PIT.
The main questions it aims to answer are:
Does PIT reduce shoulder pain and improve shoulder range of motion more effectively than conventional therapy alone?
What side effects or medical problems do participants experience when receiving PIT?
Researchers will compare PIT to conventional therapy to see if PIT works better to treat adhesive capsulitis.
Participants will:
Receive either:
PIT once weekly for 6 weeks plus physiotherapy and oral analgesics (excluding NSAIDs), or
Conventional therapy only (physiotherapy and analgesics including NSAIDs)
Attend scheduled follow-up visits at Week 6, 1 month, and 3 months after treatment
Perform daily home-based shoulder exercises and record their analgesic use and any side effects in a patient diary
Study Title:
The Impacts of Perineural Injection Therapy on Adhesive Capsulitis in a Single Centre Hospital in Selangor: A Randomized Controlled Trial Pilot Study
Study Overview :
Adhesive capsulitis, commonly known as "frozen shoulder," is a painful condition that limits shoulder movement and affects daily activities such as dressing, reaching overhead, or lifting objects. It often affects adults between the ages of 40 to 60 and can last for months or even years. For some, the condition may improve with physiotherapy and medication, but others continue to struggle with pain and stiffness.
This clinical trial aims to explore a new method of treatment called Perineural Injection Therapy (PIT). PIT involves injecting a natural sugar solution (5% dextrose) just under the skin at specific nerve areas around the shoulder. This method targets nerves that may be irritated or inflamed and helps to reduce pain and improve movement.
Although PIT has shown promising results in treating other painful conditions like nerve entrapments and joint pain, its effects on frozen shoulder have not yet been well studied. This research hopes to find out if PIT can help relieve pain, improve shoulder movement, and enhance function in people with frozen shoulder.
The current treatment options for frozen shoulder (such as physiotherapy, painkillers, and steroid injections) do not work for everyone. PIT is a non-surgical option that may help the healing process by calming nerve-related inflammation. This study will evaluate how effective PIT is and whether it is safe for use in treating adhesive capsulitis.
Participants will be randomly assigned to one of two groups:
Intervention Group: Will receive six weekly sessions of PIT combined with physiotherapy and oral pain medication (excluding NSAIDs like ibuprofen).
Control Group: Will receive only conventional therapy, including physiotherapy and standard painkillers (including NSAIDs).
All participants will:
Be evaluated for shoulder pain, range of motion, and ability to perform daily activities at the beginning of the study, at Week 6, 1-month, and 3-months after treatment.
Be taught home exercises to do daily to improve shoulder mobility and strength.
Be asked to keep a diary to record medication use and any side effects they experience.
Receive support and regular follow-ups from the research team to monitor progress and manage any issues.
Adults aged 18 and above who have been diagnosed with primary (idiopathic) adhesive capsulitis for at least 3 months and are experiencing significant shoulder pain and stiffness may be eligible. Participants must be able to understand and follow instructions in Malay or English.
People will not be eligible if they:
Have had a shoulder injection or surgery recently
Have other serious shoulder problems (like a fracture or nerve injury)
Have poorly controlled diabetes or are on certain medications that may interfere with the study
PIT is generally safe and has been used in other conditions with minimal side effects, such as mild pain or redness at the injection site. In this study, participants will be closely monitored for any adverse effects.
Potential benefits include reduced pain, improved shoulder movement, and better overall function. The information gathered may help develop better treatment options for others with frozen shoulder in the future.
Each participant will be involved in the study for approximately 3 to 4 months, including the 6-week treatment period and two follow-up assessments.
384 studies on the registry are indexed under Bursitis; 111 are open to participants now.
This study's planned enrollment of 24 is below the median of 44 across 347 interventional studies indexed under Bursitis.
Browse Bursitis studies →Universiti Teknologi Mara is the lead sponsor of 27 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Perineural injection Therapy
Other: perineural injection · Other: Physiotherapy
Physiotherapy
Other: Physiotherapy
Intervention The procedure will be performed by a rehabilitation physician who has obtained hospital-level credentialing and privileging to practice Perineural Injection Therapy (PIT). The physician has undergone hands-on training with Dr. Lyftogt-certified trainers in Malaysia. PIT will be administered weekly for six week (Total 6 sessions). In addition to this intervention, patient will also receive conventional therapy which is monthly outpatient physiotherapy with supplementary home-based exercise program, and oral analgesia (except NSAIDs). Solution: Buffered 5% dextrose. Pre injection: Chronic constriction injury points will be identified by palpation along the shoulder's cutaneous nerves - the suprascapular, supraclavicular, axillary, musculocutaneous, and radial nerves. These points will be marked to ensure precise targeting. Taking into account these nerve pathways, the maximum injection area for this research is set at 10 sites per session.
Also known as: Perineural injection therapy, PIT
Patients will be receiving a structured home-based exercise program and will be instructed on how to perform these exercises at home. The exercise regime will be 30 minutes, 3 times a day to enhance shoulder mobility and strength in addition to the regular monthly outpatient physiotherapy session. Oral analgesics exclude NSAIDs will be prescribed as needed to manage pain.
Numerical Rating Scale
Participants will rate their shoulder pain on a scale from 0 to 10, where 0 indicates "no pain" and 10 represents "worst imaginable pain."
Time frame: Measured at baseline (Week 0), post-treatment (Week 6), 1-month follow-up (Week 10), and 3-month follow-up (Week 18).
Shoulder Range of Motion (ROM)
Tool: Goniometer (standardized physical measurement) Passive ROM will be measured in four directions: forward flexion, abduction, internal rotation, and external rotation. Values will be recorded in degrees.
Time frame: Measured at baseline (Week 0), post-treatment (Week 6), 1-month follow-up (Week 10), and 3-month follow-up (Week 18).
Functional Outcome
Tool: Shoulder Pain and Disability Index (SPADI) - validated English and Malay versions A self-reported questionnaire with 13 items divided into two subscales: 5 for pain and 8 for functional disability. Each item is scored from 0 (no pain/disability) to 10 (worst pain/disability), with higher scores indicating greater impairment.
Time frame: Measured at baseline (Week 0), post-treatment (Week 6), 1-month follow-up (Week 10), and 3-month follow-up (Week 18).
Adverse Reactions
Tool: Adverse Event Reporting Form and Patient Diary Description: Side effects will be classified into: Mild: Local pain, bruising, or redness Moderate: Transient numbness, swelling, or prolonged discomfort Severe: Infection or allergic reaction
Time frame: Monitored throughout the 6-week intervention
Frequency of Analgesic Use
Tool: Patient Diary (self-recorded) Description: Participants will log each use of pain medication (type and frequency) throughout the study period.
Time frame: Recorded weekly from baseline until the 3-month follow-up.
Started Jun 2025 (actual). Primary completion is estimated for May 2026, 11 months after the start.
Of 219 non-industry interventional studies with no phase under Bursitis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's planned 11 months is close to that.
Counting every sponsor, half of 219 studies reached it within 10 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universiti Teknologi Mara